RTTNews | Oct 25, 2021 08:17AM EDT

08:17 Monday, October 25, 2021 (RTTNews.com) - Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Monday a collaboration agreement with Merck & Co., Inc. (MRK), with an option to license Xeris' suspension-based formulation technology, XeriJect, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations.

Xeris noted that the XeriJect platform has broad applicability in improving the delivery of large molecules, such as monoclonal antibodies. This is another in a series of collaborations Xeris has undertaken with top 10 pharma companies evaluating the XeriJect technology.

The terms of the agreement were not disclosed.

Read the original article on RTTNews ( https://www.rttnews.com/3235125/xeris-biopharma-in-collaboration-with-merck-on-xeriject-stock-up-18-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved